In patients hospitalised for COVID-19 with clinical hypoxia who required either no
oxygen or simple oxygen only, higher dose corticosteroids significantly increased
the risk of death compared with usual care, which included low-dose corticosteroids.
The RECOVERY trial continues to assess the effects of higher dose corticosteroids
in patients hospitalised with COVID-19 who require non-invasive ventilation, invasive
mechanical ventilation, or extracorporeal membrane oxygenation.